The present invention relates to the conjugates of Tubulysin derivatives (anologs) and cell-binding molecules using branched (side-chain) linkers, and the resulting conjugates have better pharmacokinetic properties, and thus can more accurately target and kill abnormal cells. The invention also relates to the conjugation methods of the Tubulysin derivatives (anologs) to cell-binding molecules, and methods for synthesizing the small molecules, and methods of using the conjugates for targeted therapy for cancers, infections and autoimmune diseases. The conjugates of Tubulysin derivatives with long branched linkers demonstrated increased half-life, minimal exposure to non-targeted cells, tissues or organs in system circulation, leading to reduced off-target toxicity.
本发明涉及使用支链(侧链)连接体的Tubulysin衍
生物(同源物)和细胞结合分子的共轭物,所得到的共轭物具有更好的药代动力学特性,因此可以更准确地靶向和杀死异常细胞。本发明还涉及 Tubulysin 衍
生物(同源物)与细胞结合分子的共轭方法、合成小分子的方法以及将共轭物用于癌症、感染和自身免疫性疾病靶向治疗的方法。具有长支链的 Tubulysin 衍
生物共轭物的半衰期延长,在系统循环中与非靶细胞、组织或器官的接触减少,从而降低了脱靶毒性。